| Literature DB >> 36203779 |
Pei Lu1, Junyan Pu1, Yiping Zong2, Zijie Wang1, Peng Han1, Min Gu1.
Abstract
Since 1969, an herbal medicine extracted from Quercus salicina Blume/Quercus stenophylla Makino (QS) has been clinically used for the management of urolithiasis in Japan. Historically, the decoction of leaves and shoots of QS trees was popularly utilized as a folk prescription to remove urinary calculi. This study was designed to perform a brief review of the updated progress of QS extract for urinary stones based on previous studies. A comprehensive literature search was conducted in multiple electronic databases, including Web of Science, PubMed, and EMBASE, and relevant data on QS extract were extracted. As a result, the major mechanism of QS extract for urolithiasis is observed to be closely related to the anti-oxidative activities according to recent studies, leading to inhibition of the accumulation of renal calcium and prevention of stone formation and recurrence of stones. As for the effect of discharging stones, loosening the upper urinary tract has also been noticed recently. More extensive studies are still necessary to systemically evaluate the individual dosage, drug safety, and targeted stone types.Entities:
Keywords: Quercus salicina extract; anti-oxidative; clinical application; stone formation; urolithiasis
Year: 2022 PMID: 36203779 PMCID: PMC9530443 DOI: 10.3389/fmed.2022.960292
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Major medical functions and applications of QS extract.
|
|
|
|
|---|---|---|
| Urolithiasis | Protect the renal tubular cells from the injury caused by free radicals and prevent stone formation | ( |
| Rheumatoid arthritis | Suppress oxidative stress in rheumatoid arthritis | ( |
| Anti-diabetic | Provide cytoprotective effect against oxidative stress and increase the insulin secretion of pancreatic b cells | ( |
| Cardiovascular disease | Endothelium-dependent relaxation of coronary artery | ( |
| Allergic diseases | Anti-allergic and atopic effects | ( |
Results of major research concerning the efficacy of urocalun for urinary stones.
|
|
|
|
|
|---|---|---|---|
| 1967 ( | Clinical study | 21 patients with ureteral stones, 11 patients with renal stones, all administered QS extract capsule | QS extract capsule was effective to discharge stones in 75% of the cases with ureteral stones, but no changes happened to incarcerated calyceal stones |
| 1969 ( | Double-blind controlled clinical study | 106 cases with upper urinary stones, half in placebo group and half in QS group | the stone discharge rate and stone down rate in QS group were higher than that in placebo group, and the differences were statistically significant |
| 2002 ( | Open-label clinical trial | 60 patients with ureteral calculi < 1 cm received QS extract capsule orally | 75% cases eliminated the calculi, mostly in upper and lower ureter, no stone discharge in the middle ureter |
| 2009 ( | Animal experiment | rat calcium oxalate urolithiasis, administered with QS extract | QS extract restrained the renal calcium accumulation induced by oxidative damage in kidneys |
| 2011 ( | Open-label clinical trial | 75 patients with ureteral calculi < 1 cm received QS extract capsule orally | 74% cases discharged the stones, 20% cases showed stone descending, mostly in lower ureter |
| 2015 ( | Prospective multicenter randomized controlled clinical study | 88 cases of ureteral stones, 23 cases of renal stones in QS group and 84 cases of ureteral stones, 26 cases of renal stones in control group | clinical symptoms were relieved greatly and the cure rate was higher in QS group, the QS extract capsule was safe and effective in the treatment for stones < 1 cm |
| 2015 ( | Animal experiment | 60 mice divided into 4 groups: control group, renal calcium oxalate group, low dose QS group, high dose QS group | the concentration of Ca2+ and oxalate in urine in QS groups were decreased, and the activity of SOD and GSH-Px increased, such changes were more apparent in high dose QS group, indicated that QS extract increased the stone-preventing effect and antioxidant activity |
| 2016 ( | Randomized controlled clinical study | 286 patients with urinary calculi < 1 cm divided into 2 groups: control group and QS group | in 4-week-course, the stone remove rate was significantly higher in QS group, especially in week 1 and week 2, proving significant clinical efficacy and safety in treating small urinary calculi |
| 2019 ( | Retrospective controlled clinical study | 62 cases with residual | ESWL with QS extract capsule brought higher stone discharge rate and lower retreatment rate |
| 2019 ( | Retrospective controlled clinical study | 50 cases after USL for renal stones 2–3 cm divided into QS group and control group | the stone free rate was much higher in week 2, week 3, week 4, and the stone discharge time was shorter in QS group, suggested QS extract capsule increased the stone discharge rate after USL |
| 2021 ( | Animal experiment | rat model with renal calcium oxalate stone, intervened with QS extract capsule for 4 weeks | QS extract capsule inhibited the formation of renal calcium oxalate stones, attenuating the oxidative stress process and protecting renal tubular cells by reducing autophagy and apoptosis through MPAK signaling pathway |
| 2021 ( | Randomized controlled clinical study | 148 patients with intramural ureteral stones < 1 cm divided into 3 groups: tamsulosin, tamsulosin + Potassiun sodium hydrogen citrate, tamsulosin + QS extract capsule | QS extract capsule + tamsulosin performed better efficacy for stones < 1 cm in intramural ureter than other two groups, the combination therapy was considered to be more helpful than single classical drugs |